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Summary
Objectives: To study responsiveness and establish the minimal clinically important differences (MCID) and minimal detectable change (MDC)
in patients undergoing total hip replacement (THR) using the Short Form 36 (SF-36) and the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC).
Methods: We conducted a prospective observational study in three public hospitals of all consecutive patients with a diagnosis of hip
osteoarthritis (OA) on waiting lists to undergo THR. Patients completed the SF-36 and the WOMAC (subscales transformed to 0 to 100), which
measured the health-related quality of life (HRQoL), before intervention and 6 months and 2 years later, and additional transitional questions,
which measured the changes in the joint 6 months postoperatively.
Results: Improvements at 6 months after a THR were between 37 (stiffness) and 39 points (pain), depending on the WOMAC domain. The
SF-36 domains also showed improvements: physical function (31.91), physical role (33.71), and bodily pain (29.77). From 6 months to 2 years,
improvements ranged from 2 to 5 points, except for role physical (13.25). A ceiling effect was detected on some WOMAC domains as well as
a ﬂoor effect on the SF-36. The MCID ranged from 25.91 (stiffness) to 29.26 (pain) on the WOMAC and from 10.78 (physical role) to 20.40
(physical function) on the SF-36. The MDC ranged from 21.38 (pain) to 27.98 (stiffness) on the WOMAC and from 18.99 (physical function) to
42.05 (social function) on the SF-36.
Conclusions: These values indicate expected gains after THR. However, the MCID and MDC values must be viewed cautiously due to the
uncertainty of these estimators and should not be considered as absolute thresholds.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIn the ﬁeld of rheumatology, the measurement of outcomes
by health-related quality of life (HRQoL) questionnaires has
become commonplace. Most studies that focused on
outcomes on patients with osteoarthritis (OA) would have
been considered inappropriate if the adequate HRQoL tools
had not been routinely used. Although the HRQoL ﬁeld
is continuously improving, most researchers recommend
using one generic HRQoL tool, such as the popular Medical
Outcomes Short Form 36 Health Survey (SF-36)1, and one
speciﬁc tool2e4, such as the Western Ontario and the
McMaster Universities Osteoarthritis Index (WOMAC)5. The
WOMAC is a well-known HRQoL-speciﬁc instrument de-
veloped for use in patients with OA of the hips and knees.
These tools have been used in several longitudinal studies
with patients undergoing total hip joint replacement
(THR)6,7. In most cases, follow-up was at 6 months, 1
year, 2 years, or longer3,8e11.
The responsiveness of these HRQoL instruments is
a necessary psychometric property to study to show that
the instruments can measure real changes after a thera-
peutic intervention. The responsiveness of the SF-36 and
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Received 4 May 2005; revision accepted 30 June 2005.1the WOMAC has been evaluated in several studies in
different diseases and using different SF-36 versions and
languages3,12,13. The minimal clinically important difference
(MCID) and the minimal detectable change (MDC) are
concepts related to responsiveness but are more clinically
or individually oriented14e16, which is currently an important
area of research in the HRQoL measurement ﬁeld. Even in
rheumatology, the MCID, the MDC, and the responsiveness
of the SF-36 and the WOMAC have already been studied in
different settings. However, most studies have concentrated
on pharmacologic interventions, due to the interest in
clinical trials17,18, or the results of rehabilitation19. A few
studies have evaluated those parameters after a THR3,20,21
but to the best of our knowledge, the MCID and MDC of
both instruments have not been evaluated simultaneously.
We conducted a prospective observational study with
these two popular HRQoL tools using a large patient
sample to provide more information about the responsive-
ness of the SF-36 and the WOMAC in patients undergoing
THR.
Patients and methods
This prospective observational study took place in three
public teaching hospitals of the Basque Health Service-
Osakidetza, a local government agency in the Basque076
1077Osteoarthritis and Cartilage Vol. 13, No. 12Country, which is part of the Spanish National Health
Service. The ethics review board of our institution approved
the study.
Consecutive patients undergoing primary THR by hip OA
between March 1999 and March 2000 and who were fol-
lowed in any of the three hospitals were eligible for the
study. Patients with malignant, severe organic, or psychi-
atric diseases were excluded.
We collected data from the hospital medical records and
directly from the patients. To retrieve data from the
medical records we developed data-collection question-
naires that included among them sociodemographic data,
the primary patient complaint, and comorbidities (all those
included on the Charlson comorbidity index22). All patients
on the waiting list for THR received a letter informing them
of the study and asking for their voluntary participation.
They received the SF-36 and WOMAC questionnaires by
mail. A reminder letter was sent to those patients who had
not replied after 15 days; we then sent the questionnaire
again and contacted those by phone who still had not
replied after another 15 days. Six months and 2 years
after the intervention, patients received the same ques-
tionnaires and a transitional question (anchor question).
The follow-up for those not responding was as described
previously.
The SF-36 is a generic HRQoL instrument for measuring
the quality of life1. Its 36 items cover eight domains
(physical function, physical role, bodily pain, general health,
vitality, social function, emotional role, and mental health)
and can be incorporated into two physical and mental
summary scales. The SF-36 scores range from 0 to 100,
with a higher score indicating better health status. In
addition, normalized values can be estimated so that it
can provide a reference value from the general population.
To do so, each SF-36 component score ﬁrst was
standardized using the mean and standard deviations
(SD) obtained from a Spanish population older than 45
years and then transformed to norm-based (meanZ 50,
SDZ 10) scoring, as suggested by the authors of the
questionnaire23. The SF-36 has been translated into
Spanish and validated in Spanish populations and the
measurement properties were published previously24. We
also estimated utilities based on the SF-36, referred to as
the SF-6D25.
The WOMAC is a disease speciﬁc, self-administered
questionnaire developed to study patients with hip or knee
OA that requires about 5 min to complete5. It has a multi-
dimensional scale comprising 24 items grouped into three
dimensions: pain (5 items), stiffness (2 items), and physical
function (17 items). We used the 3.1 Likert version with
ﬁve response levels for each item, representing different
degrees of intensity (none, mild, moderate, severe, or
extreme) scored from 0 to 4. The ﬁnal WOMAC score was
determined by adding the aggregate scores for pain,
stiffness, and function. The data were standardized to
a range of values from 0 to 100, where 0 represents the
best health status and 100 the worst health status. A
reduction in the overall score represented an improvement.
The original questionnaire is reliable, valid, and sensitive to
the changes in the health status of patients with hip or knee
OA12. The WOMAC has been translated into Spanish and
validated in Spain26.
All patients answered a transitional question about their
joint improvement after the intervention. The possible
responses included ‘‘a great deal better,’’ ‘‘somewhat
better,’’ ‘‘equal,’’ ‘‘somewhat worse,’’ or ‘‘a great deal
worse’’15.STATISTICAL ANALYSIS
The unit of study was the patient. In cases in which two
interventions were performed in one patient during the
recruitment period, we selected the ﬁrst THR intervention
done to the patient: 469 patients with THR (Fig. 1).
Descriptive statistics included frequency tables, means
and standard deviations. Chi-square and Fisher’s exact
tests were used to test for statistical signiﬁcance among
proportions. For continuous variables (e.g., age and length
of stay), analysis of variance (ANOVA) was performed in
the univariate analysis. We used the paired t test for the
comparison between before the intervention and 6 months
to 2 years after THR. To study the effect of comorbidities on
the HRQoL improvement, we performed ANOVA, with
Scheffe’s test for multiple comparisons, and the Kruskale
Wallis non-parametric test because some of the domains
present a non-normal distribution. The dependent variable
was the HRQoL improvement in each domain of the two
questionnaires. The independent variable was the Charlson
comorbidity index categorized as 0, 1, and R2, and the
score before the intervention in that domain.
We estimated the ﬂoor and ceiling effect for the SF-36
and WOMAC before the intervention and at 6 months and 2
years after the intervention. A ceiling effect occurs when
a high proportion of the total respondents grade themselves
as having the maximum score in the instrument. Inversely,
a ﬂoor effect occurs when again a high proportion of
respondents grade themselves at the minimum score. To
867 On waiting list
586 Fulfilled selection criteria 
485 (82.8%) Accepted to participate 
474 (97.7%) Medical record accessible 
469 (98.9%) Patients with first intervention 
379 (80.8%) Responder 6 months after
discharge
310 (66.1%) Responder 2 years after
discharge 
281 Excluded:
178 No osteoarthritis 
  40 Severe disease 
  63 No Intervention 
Samples
included in
this study
Fig. 1. Patient recruitment and losses. Patients were excluded if
their main diagnosis was not hip OA; if they had malignant, severe
organic, or psychiatric diseases; or if they did not undergo surgical
intervention, for any reason (death, intervention in other hospital,
refusal of the intervention), 1 year after inclusion in the study. Each
percentage (in parentheses) is estimated based on the previous
frequency except for response rate at 2 years, which was based on
the 469 patients who entered the study.
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statistics were estimated for both questionnaires27.
To measure responsiveness, we used the following
indexes: effect size, deﬁned as the mean change in the
patient score with improvement divided by the SD of the
baseline scores; the standardized response mean, deﬁned
as the mean change in the patient score with improvement
divided by the SD of the changed scores; and the Guyatt
Responsiveness Index (GRI) which is deﬁned as the ratio of
average change in patients identiﬁed as improved divided
by the standard deviation of the change in patients
identiﬁed as remaining stable based on the average global
rating of change12.
Those who answered ‘‘somewhat worse’’ or ‘‘a great deal
worse’’ to the transitional question were combined because
the sample size of both was very small. The MCID has been
deﬁned28 as the smallest difference between the scores in
a questionnaire that the patient perceives to be beneﬁcial.
The MCID was calculated for those patients who, at visit at
6 months, declared changes ‘‘somewhat better’’ in the
general health status item (difference between the scores
from baseline and the visit at 6 months). To estimate the
MCID, we estimated the change from before the interven-
tion to 6 months and 2 years after the intervention. The
MCID was established by taking the change for those who
answered ‘‘somewhat better’’16. We estimated the MCID
proportion (MCID%), which is the proportion of the sample
with a change in scores exceeding the MCID. We estimated
the standardized error of measurement (SEM) by the formula
SEMZ SD[(1R)1/2], where SD is the baseline SD and R is
the testeretest reliability coefﬁcient from a previous
analysis. With the SEM, we calculated the reliable change
index, also called the minimal detectable change (MDC)14.
The MDC expresses the minimal magnitude of change
above or below which the observed change is likely to be
real and not just measurement error. For its calculation only
the changes detected in stable persons are used. The error
calculation for a measured value was obtained by multiply-
ing the point estimate for the SEM by the z-value associated
with the 95% conﬁdence interval (zZ 1.96). To calculate
the MDC95, the value obtained from the error calculation
was multiplied by the square root of two (i.e., MDC95Z
SEM! 1.96! O2). The interpretation of the MDC95 is that
95% of truly stable patients demonstrate a random variationof less than this magnitude when assessed on multiple
occasions. A change greater than MDC95 is interpreted as
a true change. We estimated the reliable change proportion
or the MDC proportion (MDC%), which is the proportion
of the sample with a change in scores exceeding the
MDC95.
All statistical analyses were performed using SAS for
Windows statistical software, version 8.2 (SAS Institute,
Inc., Cary, NC).
Results
During the 1-year recruitment, 867 patients were placed
on waiting lists to undergo primary THR. Of these, 281 were
excluded. Of the 586 patients who fulﬁlled the selection
criteria, 485 patients agreed to participate and completed
the questionnaires sent to them before the intervention.
Of these, 474 had accessible medical records and
they presented with hip OA. We included 469 patients
who had undergone a THR ﬁrst time, of which 379 (80.8%)
completed the questionnaires before and 6 months after the
intervention and 310 (66.1%) completed the questionnaires
2 years after the intervention. These are the samples
included in this study. Figure 1 includes the patients lost
during the recruiting process. There were no statistically
signiﬁcant differences between the responders and the non-
responders in sociodemographic variables and main clinical
characteristics, including pain or functional limitation,
6 months after the intervention.
The mean patient age was 69.4 years (STD, 8.8).
Women represented 50.7% of the study population,
61.4% of the participants had no comorbidities, and 29%
had a Charlson comorbidity index of 1 and 9.6% had 2 or
higher. Length of stay for the whole sample was 10.7 days
(STD, 2.9).
Six months after THR, improvements were higher than 37
points on all WOMAC domains and about 30 or higher on
the main physical domains of the SF-36 (physical function,
physical role, and bodily pain) (Table I). Other SF-36
domains, i.e., social function or vitality, had improvements
of about 20 points; the mental domains (emotional role and
mental health) and the general health domain had the
lowest improvements. Two years after the intervention,Table I
Changes after THR in HRQoL at 6 months and 2 years
Pre-intervention
x (STD)
(nZ 469)
At 6 months
x (STD)
(nZ 379)
P value At 2 years
x (STD)
(nZ 310)
P value
WOMAC
Pain 54.68 (18.71) 15.11 (16.04) !0.001 12.28 (17.31) !0.001
Functional limitation 64.73 (16.27) 26.65 (18.15) !0.001 22.36 (19.40) !0.001
Stiffness 58.01 (23.16) 19.82 (18.61) !0.001 15.51 (18.94) !0.001
SF-36
Physical function 21.47 (20.66) 54.49 (24.95) !0.001 56.31 (28.03) !0.001
Role physical 10.95 (27.31) 44.08 (44.59) !0.001 59.52 (43.67) !0.001
Bodily pain 31.02 (25.97) 61.54 (29.37) !0.001 64.68 (29.75) !0.001
General health 58.65 (19.62) 63.93 (20.01) !0.001 61.65 (22.23) 0.1231
Social function 55.18 (31.63) 78.93 (24.73) !0.001 79.40 (24.71) !0.001
Role emotional 67.00 (44.67) 82.17 (36.99) !0.001 82.09 (35.75) !0.001
Vitality 42.68 (23.58) 62.35 (24.03) !0.001 62.45 (25.25) !0.001
Mental health 59.96 (23.34) 73.54 (22.33) !0.001 73.35 (22.43) !0.001
Utility SF-6D 0.53 (0.13) 0.69 (0.16) !0.001 0.71 (0.16) !0.001
Change at 6 months or 2 years refers to the change in each domain compared to the score before intervention.
1079Osteoarthritis and Cartilage Vol. 13, No. 12there were still minor improvements after 6 months on both
HRQoL questionnaires. In the case of the WOMAC
domains, all those improvements were statistically signiﬁ-
cant. In the case of the SF-36, just the role physical and
physical summary scale. The general health domain
worsened (PZ 0.003).
Figure 2 shows the evolution of the SF-36 normalized
scores for all domains from before the intervention to
6 months and up to 2 years after the intervention. The
reference score of the general population older than 45
years old was 50 points. Some domains, such as physical
function, physical role, bodily pain, and social function, had
important improvements. Nevertheless, none of them
reached 50. Emotional role, vitality, and mental health
showed some improvements at 6 months, but remained
similar at 2 years, with values similar to those of the general
population. The general health domain score was similar to
the general population before the intervention, and after-
ward the improvements were minor.
We did not detect differences in the HRQoL improvement
between the three categories of the Charlson comorbidity
index for any WOMAC or SF-36 domain in patients who
underwent THR.
The WOMAC presented minor ﬂoor or ceiling effects
before the intervention, although the ﬂoor effect was
present in the stiffness and pain domains at 6 months and
2 years (Table II). The SF-36 domains presented ﬂoor and
ceiling effects before the intervention, while afterward the
ﬂoor effect dominated. Physical role, social function,
emotional role, and bodily pain were the domains in which
those problems predominated. Both questionnaires had
a Cronbach alpha higher than 0.70 in all domains.
The different responsiveness parameters evaluated at 6
months and 2 years after the intervention were above 0.80
for all WOMAC domains. In the SF-36, most domains had
effect sizes and standardized response mean values higher
than 0.7, except mental health, emotional role, or, signiﬁ-
cantly, general health, which were below 0.7 (Table III). The
GRI had the lowest value and was more signiﬁcantly
different.
0
10
20
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40
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Pre-Intervention At 6 months At 2 years
Fig. 2. Changes in normalized SF-36 values. SF-36 domains: PF:
physical function; RP: role physical; BP: bodily pain; GH: general
health; SF: social function; RE: role emotional; VT: vitality; MH:
mental health. 50: reference score of general population older than
45 years.All patients answered a transitional question at 6 months
and 2 years about the improvement in their hip after the
intervention. This question was used as an anchor to
establish the MCID for patients undergoing THR. To do so,
we used the answer ‘‘somewhat better’’ to establish the
MCID for improvement. At 6 months (Table IV), the MCID
for the WOMAC domains exceeded 25 points. With the
SF-36, the MCID ranged from 0.40 for general health to
20.40 for physical function. The MCID% was higher than
70% for all WOMAC domains, except stiffness (60%), while
it was higher than 50% in all the SF-36 domains.
The improvement among those who responded ‘‘a great
deal better’’ was more homogeneous and higher. For
the WOMAC, improvements exceeded 40 points for all
domains. With the SF-36, the physical function, physical
role, and bodily pain domains had greater improvements
(above 33 points).
We estimated the MDC from the SEM and then calculated
the MDC%. The MDC% was higher than 80% for all
WOMAC domains, except stiffness (60%), while it was
higher than 40% in the physical domains of the SF-36
(physical function, physical role, or bodily pain).
Table V shows the previous parameters estimated at 2
years. At this time, MDC% and MCID% were similar to
those at 6 months, although slightly higher.
Discussion
The results of this prospective study of a large sample of
patients with hip OA who underwent THR provided
additional information about the responsiveness of two
well-known HRQoL instruments, but in their Spanish
versions. However, the study mainly provides information
about the MCID and MDC in patients undergoing those
interventions. This is a way to provide clinical meaning to
the scores provided by these HRQoL tools. It also provides
information on the follow-up of patients up to 2 years after
the intervention.
As other studies also have reported, the main change
after THR can be detected at 6 months8,11. The mean
improvements measured by the WOMAC and the physical
domains of the SF-36 are impressive. Even the SF-36
mental domains indicated improvements exceeding 10
points in most cases. The only exception was the general
health domain, which had the poorest gains after both
interventions.
From 6 months to 2 years after the intervention,
improvements were minor or there were even losses in
some domains. The WOMAC showed improvements from
6 months to 2 years ranging from 2 to 4 points. In addition,
the improvements were minor (less than 3 points) in the
SF-36 domains, except for physical role, which had higher
gains, and general health, which had losses that might
reﬂect other patient comorbidities. Nevertheless, we studied
the effect of the comorbidities on the improvement, but we
did not ﬁnd differences among our three categories of the
Charlson comorbidity index.
The inﬂuence of the comorbidity status on the outcomes
could be reﬂected, basically, in the general health domain of
the SF-36, since most common comorbidities will impact on
that domain. The main impact on those physical domains of
the SF-36 (physical function, bodily pain or role physical) as
well as in the WOMAC should be attributed to the hip OA
and less to other comorbidities. We used the Charlson
comorbidity index since it is one of the most popular and
well known among all comorbidity indexes. But the
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HRQoL questionnaires’ psychometric properties after THR at 6 months and 2 years
Pre-intervention At 6 months At 2 years Cronbach alpha
% Floor % Ceiling % Floor % Ceiling % Floor % Ceiling
WOMAC
Pain 0.43 1.28 25.20 0.27 39.54 0.33 0.83
Functional limitation 0.21 0 4.86 0 8.52 0.00 0.93
Stiffness 2.58 7.1 30.91 0.54 46.91 0.33 0.81
SF-36
Physical function 15.33 0.22 1.10 1.66 3.29 4.28 0.89
Role physical 82.47 6.17 43.50 33.53 29.25 46.60 0.91
Bodily pain 15.95 4.74 2.20 24.18 2.34 30.10 0.72
General health 0 0.66 0.28 3.31 0.67 2.68 0.74
Social function 7.16 17.35 1.09 43.44 1.00 44.85 0.77
Role emotional 28.04 62.03 15.81 79.64 13.61 77.55 0.94
Vitality 5.18 1.13 0.59 7.96 2.07 7.59 0.77
Mental health 0.68 4.97 0 13.39 1.05 13.29 0.87
Utility SF-6D 1.23 0 0 1.34 0 2.72 0.78
Floor (proportion on lowest score) and ceiling (proportion on highest score).Charlson comorbidity index was intended as a mortality
predictor and, therefore, we should not expect important
changes.
Additionally, Fig. 2 clearly shows that the scores of the
general health domain of these patients are already similar
to those of the general population (50 points) even before
the intervention, meaning that there is not much room for
improvement. Related to this, some of the other respon-
siveness parameters of this domain showed very poor
results due to the fact that this domain did not show
improvement: may be because that is the higher score they
can have. The ﬂoor and ceiling effect for that domain were
reasonably good (close to 0%). Nevertheless, the worsen-
ing from 6 months to 2 years in the general health domain
could be attributed to addition of new comorbidities. But we
were not able to check this hypothesis.
Regarding the ﬂoor and ceiling effects of both question-
naires, there seems to be room for improvement in both
tools. As some authors pointed out29, 15% would be
a critical value for the largest proportion of patients who
should score the highest or lowest possible scores.
Therefore, the WOMAC presented an important ﬂoor effect
Table III
Responsiveness and MCID parameters after a THR at 6 months
At 6 months At 2 years
ES SRM GRI ES SRM GRI
WOMAC
Pain 2.10 1.86 1.10 2.24 1.98 2.18
Functional limitation 2.34 1.80 1.45 2.58 1.97 1.79
Stiffness 1.61 1.39 0.81 1.81 1.53 1.12
SF-36
Physical function 1.54 1.10 1.54 1.60 1.10 0.50
Role physical 1.23 0.74 e 1.72 0.99 0.26
Bodily pain 1.15 0.91 0.04 1.26 0.96 0.63
General health 0.25 0.27 0.03 0.09 0.09 0.35
Social function 0.72 0.71 0.37 0.74 0.69 0.44
Role emotional 0.29 0.26 0.13 0.31 0.30 e
Vitality 0.80 0.78 0.55 0.79 0.73 0.83
Mental health 0.54 0.54 0.54 0.56 0.60 0.99
Utility SF-6D 1.23 1 0.69 1.38 1.13 0.88
ES: effect size; SRM: standardized response mean; GRI: Guyatt
responsiveness index.after the intervention in the pain and stiffness domains, and
ceiling in the SF-36 role physical and emotional, bodily pain,
and social function. Those domains have in common that
they include few items or their scores act almost as
a categorical variable. Those domains probably need the
introduction of new items to reduce these effects. All of
these domains are relevant when evaluating changes in
these patients. These two tools might be limited in their
capacity to capture higher gains, as with the WOMAC which
seems to correctly discriminate patients with advanced hip
OA, but has limitation in patients with no or minor pain. This
may explain why we only captured minor changes from
6 months to 2 years, although the functional limitation of the
WOMAC and the physical function of the SF-36 seem to
have relatively low ﬂoor and ceiling effects and did not
detect important gains between the two time points.
The results of the responsiveness parameters with the
WOMAC are impressive since all parameters that mea-
sured the effect size were above the minimum required for
good responsiveness (O0.70)30. The SF-36 also showed
very good results in the physical domains, which are the
relevant domains that should improve after these inter-
ventions. However, as with previous studies12,13, the
disease-speciﬁc WOMAC had better responsiveness
results than the SF-36. This is the advantage of speciﬁc
HRQoL instruments over generic tools, such as the SF-
3621. We also must highlight the important discrepancies
among the three effect size responsiveness parameters,
especially with the GRI. This also was reported pre-
viously31 and must be associated with the way the GRI
is constructed. To construct the GRI only those who
answered ‘‘somewhat better’’ to the transitional question
were included in the nominator. For the other indexes
[SES, standardized response mean (SRM)], all patients
were included. Taking into account that most patients
undergoing this intervention indicated that they had ‘‘a
great deal improvement’’, and worsening was rare, the
numerator always is greater for the SES or SRM than for
the Guyatt. On the other hand, the denominator of all three
indexes (SES (standard deviation pre-intervention) or SRM
(standard deviation of change) than the Guyatt (standard
deviation of those who were stable)), though different in
their construction, was quite similar or even higher for the
Guyatt in our case, due to the small sample size of the
category ‘‘somewhat better’’.
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t.An important issue from the clinical standpoint is the
establishment of clinically relevant individual gains when
using these two HRQoL tools. Statistically signiﬁcant
changes or noteworthy effect sizes at the group level may
not be signiﬁcant at the individual level16. This is where the
MCID and MDC play an important role. Various studies
have reported the MCID with both HRQoL tools after
pharmacologic interventions in patients with hip OA17,18.
One study18 reported the MCID for the WOMAC visual
analogue scale and suggested a minimum of 10 mms.
Other studies also focused on patients undergoing physical
rehabilitation19. In this case, the MCIDs were about 1.33
on a scale of 0 to 10 for the WOMAC domains but about
2 to 7.8 for the SF-36 domains. Our results for patients
undergoing THR showed much higher values for both
questionnaires. MCID results for OA patients from our study
are different from those obtained from clinical trials or
rehabilitation programs attributable to low risks and ex-
tremely high beneﬁts of THR intervention. Potential
implication is that THR interventions need to be evaluated
by parameters from this or similar studies taken from
THR studies, not from Non-Steroid Anti-Inﬂammatory Drugs
studies.
Based on our results, the MCID at 6 months is at least 25
points (scale 0e100) for the WOMAC domains in patients
who underwent THR. With the SF-36, the results were more
varied, ranging from 8 to 10 points for most mental domains
to 10 to 20 for the physical domains. Importantly, when we
asked patients about the changes in their hip, most reported
‘‘a great deal better.’’ The group of patients who responded
that they were ‘‘somewhat better’’ was small, which partly
limited our conclusions about the MCID, since we based
the MCID on this category of the transitional question.
Moreover, those who said that they feel ‘‘equal’’ or ‘‘worse’’
than before the intervention were even fewer. In the last
case, we combined those who answered ‘‘somewhat
worse’’ or ‘‘a great deal worse,’’ because the sample size
was very small and did not allow us to have two separate
categories. As an anchor question (transitional question) we
used a Likert scale with ﬁve options ranging from ‘‘a great
deal better’’ to ‘‘a great deal worse.’’ Other authors32 sug-
gested having a 15-option scale, while others used ﬁve33.
Considering the high mean age of our patients and their low
educational level, this option would have made responding
to the questionnaire more complicated. In addition, the
sample size in some categories would probably have been
minuscule or even 0 in some cases, considering our results.
Some of the reasons that there are such inter-study
differences in the calculated MCID could be that: the MCID
is function of the methods used for establishing it; most
patients included in the present study presented with severe
OA; THR is an extremely effective intervention that
produces an important change in the HRQoL of patients;
and also that the subgroup used to obtain MCID included
a weak number of patients (nZ 43).
An additional limitation of our method is that we used only
one global question, not one for each domain, as suggested
previously32,33. This would have increased the length of the
questionnaire and the percentage of non-responders or
unanswered items. In addition, transitional questions have
been criticized for being inconsistent or unstable about
responsiveness and subject to recall bias16. When consid-
ering these results for the MCID, these limitations must be
kept in mind.
Finally, the MCID and MDC results matched in some
cases, but differed considerably in others, possibly due to
the way each of the two parameters are constructed. The
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Relevant changes on HRQoL outcomes for patients undergoing total hip replacement
At 2 years
A great deal better
(nZ 254)
Somewhat better
(nZ 33)
Equal
(nZ 8)
Worse
(nZ 10)
P value MDC% MCID%
WOMAC
Pain 44.78 (19.20) 33.13 (19.04) 20.63 (15.22) 6.94 (34.04) !0.001 257 (84.26) 221 (69.18)
Functional limitation 45.87 (18.90) 25.93 (18.04) 4.59 (14.52) 20.98 (26.48) !0.001 273 (90.10) 238 (78.55)
Stiffness 44.92 (26.04) 33.20 (18.68) 3.13 (29.69) 25.00 (40.98) !0.001 197 (64.80) 197 (64.80)
SF-36
Physical function 38.60 (28.00) 8.29 (29.67) 5.00 (16.48) 15.00 (26.73) !0.001 213 (70.76) 244 (81.06)
Role physical 54.21 (45.51) 11.00 (36.14) 6.25 (41.73) 10.00 (54.77) !0.001 159 (62.35) 159 (62.35)
Bodily pain 37.02 (32.80) 18.34 (27.06) 7.38 (29.20) 12.00 (28.66) !0.001 134 (45.27) 195 (65.88)
General health 3.03 (19.72) 6.37 (13.21) 5.32 (18.07) 8.00 (12.40) 0.0076 25 (8.47) 209 (70.85)
Social function 25.80 (33.23) 17.97 (29.77) 9.38 (41.05) 15.63 (37.65) 0.0888 76 (25.42) 162 (54.18)
Role emotional 14.08 (45.33) 20.83 (62.80) 0.00 (0.0) 5.56 (71.23) 0.6441 69 (27.27) 69 (27.27)
Vitality 20.08 (25.69) 14.51 (23.77) 7.62 (17.42) 4.29 (16.44) 0.1049 84 (30.00) 157 (56.07)
Mental health 14.06 (21.44) 16.15 (20.97) 4.57 (16.24) 4.00 (21.04) 0.0132 92 (33.09) 107 (38.49)
Utility SF-6D 0.20 (0.16) 0.14 (0.12) 0.05 (0.16) 0.06 (0.09) !0.001 119 (51.52) 138 (59.74)
Means and, in parenthesis, standard deviations.
The category of worse included two answer categories: ‘‘Somewhat worse’’ and ‘‘A great deal worse’’. Somewhat betterZminimally clinical
important difference or MCID; MDC%: minimal detectable change percent; MCID%: minimal clinical important difference percent.MCID is based on the subjective answer to an anchor
score, and the MDC is based on the SEM, which depends on
the accuracy and variability of its components.
Our study had other limitations. The main problem with
a prospective design is the percentage of non-respond-
ents or missing values. In our case, we had a good
response rate before the intervention, at 6 months (higher
than 80%) and 2 years (66.1%). However, we lost one-
third of the patients from those who fulﬁlled the selection
criteria. This is standard in large follow-up studies. In all
subsequent follow-ups, at 6 months and 2 years, we send
two reminders and contacted non-respondents by tele-
phone. When comparing those who responded with those
who did not, we found no differences in the most relevant
variables. Therefore, although a bias may be present in
our study due to those losses, we think it likely is minor
and that our results can be generalized to the entire
sample.
In conclusion, the results of this study provide new
information about the MCID and MDC that should be
expected in patients undergoing a THR, allowing clinicians
to interpret the results obtained with these HRQoL tools.
This may facilitate their use not only in research but also in
clinical practice. A caveat is that the MCID and MDC values
must be considered with caution due to the uncertainty of
these estimators and should not be taken as absolute
thresholds16. As some authors have indicated, establishing
an MCID or MDC cut-off seems to be a difﬁcult or im-
possible task34.
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